|
US6756038B1
(en)
*
|
1997-10-10 |
2004-06-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
|
|
WO2001024832A2
(de)
*
|
1999-09-27 |
2001-04-12 |
Gabriele Pecher |
Pharmazeutische zusammensetzung zur behandlung und prophylaxe von humanen tumoren, die das tumorantigen muzin und/oder das carcinoembryonale antigen (cea) exprimieren und ihre verwendung
|
|
ATE391726T1
(de)
*
|
1999-10-22 |
2008-04-15 |
Sanofi Pasteur Ltd |
Modifiziertes gp100 und dessen verwendung
|
|
US7449557B2
(en)
|
2000-06-02 |
2008-11-11 |
University Of Connecticut Health Center |
Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
|
|
US7179462B2
(en)
|
2000-06-02 |
2007-02-20 |
University Of Connecticut Health Center |
α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
|
|
US7186515B1
(en)
|
2000-06-02 |
2007-03-06 |
University Of Connecticut Health Center |
Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof
|
|
JP2004524004A
(ja)
*
|
2000-07-31 |
2004-08-12 |
アヴェンティス パストゥール リミテッド |
修飾ｃｅａおよびその使用
|
|
US7025968B2
(en)
|
2000-08-30 |
2006-04-11 |
Chemocentryx, Inc. |
CMV vaccines
|
|
EP1320620B1
(en)
|
2000-09-25 |
2015-01-21 |
The Regents Of The University Of Michigan |
Production of viral vectors
|
|
EP1364037A4
(en)
|
2001-02-02 |
2005-08-03 |
Chemocentryx Inc |
METHODS AND COMPOSITIONS USEFUL IN STIMULATING AN IMMUNE RESPONSE
|
|
WO2003008537A2
(en)
*
|
2001-04-06 |
2003-01-30 |
Mannkind Corporation |
Epitope sequences
|
|
US7414032B2
(en)
|
2001-06-25 |
2008-08-19 |
Immunofrontier, Inc. |
Vaccine comprising a polynucleotide encoding an antigen recognized by a CD4+ helper T-cell and a polynucleotide encoding a tumor specific or associated antigen recognized by a CD8+ CTL
|
|
WO2004058157A2
(en)
|
2002-12-16 |
2004-07-15 |
Globeimmune, Inc. |
Yeast-based vaccines as immunotherapy
|
|
EP1660119A2
(en)
*
|
2003-09-05 |
2006-05-31 |
Sanofi Pasteur Limited |
Multi-antigen vectors for melanoma
|
|
US8562970B2
(en)
*
|
2003-10-08 |
2013-10-22 |
Sanofi Pasteur Limited |
Modified CEA/B7 vector
|
|
ES2476990T3
(es)
*
|
2003-11-12 |
2014-07-15 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Sistema para tratar y prevenir cáncer de mama
|
|
AU2004289368B2
(en)
|
2003-11-12 |
2010-08-26 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Custom vectors for treating and preventing pancreatic cancer
|
|
US20090156519A1
(en)
*
|
2003-12-23 |
2009-06-18 |
Aventis Pasteur, Inc. |
Modified KSA and Uses Thereof
|
|
US7785875B2
(en)
|
2004-07-03 |
2010-08-31 |
Mogam Biotechnology Research Institute |
Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
|
|
KR100790646B1
(ko)
*
|
2004-07-03 |
2008-01-02 |
재단법인 목암생명공학연구소 |
세포매개 면역반응을 효과적으로 유도하는 ｈｃｖ수퍼타입 에피토프, 그를 코딩하는 올리고뉴클레오타이드및 그의 용도
|
|
ES2313807B1
(es)
*
|
2005-07-30 |
2009-12-23 |
Consejo Superior De Investigaciones Cientificas |
Vectores recombinantes basados en el virus vaccinia modificado de ankara (mva) como vacunas contra la leishmaniasis.
|
|
EP1792996A1
(en)
*
|
2005-12-01 |
2007-06-06 |
Consejo Superior de Investigaciones Cientificas |
Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV)
|
|
EP2856876B1
(en)
|
2007-03-30 |
2018-01-31 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
|
|
WO2009006479A2
(en)
|
2007-07-02 |
2009-01-08 |
Etubics Corporation |
Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
|
|
EP2207564B1
(en)
*
|
2007-10-18 |
2016-10-05 |
Bavarian Nordic A/S |
Use of mva to treat prostate cancer
|
|
US8475790B2
(en)
|
2008-10-06 |
2013-07-02 |
Bristol-Myers Squibb Company |
Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
|
|
AU2008363648B9
(en)
*
|
2008-10-31 |
2013-08-22 |
Tremrx, Inc. |
Vaccination with poxvirus vectors via mechanical epidermal disruption
|
|
US8691502B2
(en)
|
2008-10-31 |
2014-04-08 |
Tremrx, Inc. |
T-cell vaccination with viral vectors via mechanical epidermal disruption
|
|
CA2759013C
(en)
|
2009-04-17 |
2021-10-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination immunotherapy compositions against cancer and methods
|
|
MX352892B
(es)
|
2011-08-17 |
2017-12-13 |
Globeimmune Inc |
Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas.
|
|
US9605276B2
(en)
|
2012-08-24 |
2017-03-28 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
|
CN105431157A
(zh)
|
2013-06-14 |
2016-03-23 |
普赛奥克苏斯治疗公司 |
用于b型腺病毒的给药方案及制剂
|
|
ES2661132T3
(es)
|
2013-10-25 |
2018-03-27 |
Psioxus Therapeutics Limited |
Adenovirus oncolíticos armados con genes heterólogos
|
|
HUE056105T2
(hu)
*
|
2013-11-28 |
2022-01-28 |
Bavarian Nordic As |
Készítmények és eljárások fokozott immunválasz indukálására poxvírusvektorok alkalmazásával
|
|
JP5917626B2
(ja)
*
|
2014-07-28 |
2016-05-18 |
トレムアールエックス， インコーポレイテッド |
機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種
|
|
CA2973109A1
(en)
|
2015-01-09 |
2016-07-14 |
Etubics Corporation |
Methods and compositions for ebola virus vaccination
|
|
WO2016112195A1
(en)
*
|
2015-01-09 |
2016-07-14 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
|
US11149087B2
(en)
|
2015-04-20 |
2021-10-19 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
|
KR102643574B1
(ko)
*
|
2015-04-30 |
2024-03-06 |
싸이오서스 테라퓨틱스 엘티디. |
B7 단백질을 암호화하는 종양세포붕괴 아데노바이러스
|
|
EP3389683B8
(en)
|
2015-12-17 |
2023-05-03 |
Akamis Bio Limited |
Virus encoding an anti-tcr-complex antibody or fragment
|
|
AU2017233072B2
(en)
*
|
2016-03-18 |
2020-12-24 |
Nantcell, Inc. |
Multimodal vector for dendritic cell infection
|
|
EP3463440A4
(en)
*
|
2016-05-27 |
2020-04-15 |
Etubics Corporation |
NEOEPITOP VACCINE COMPOSITIONS AND METHOD FOR USE THEREOF
|
|
GB201713765D0
(en)
|
2017-08-28 |
2017-10-11 |
Psioxus Therapeutics Ltd |
Modified adenovirus
|
|
MY197324A
(en)
|
2016-08-29 |
2023-06-13 |
Akamis Bio Ltd |
Adenovirus armed with bispecific t cell activator
|
|
KR20200144540A
(ko)
*
|
2018-03-06 |
2020-12-29 |
페프박스, 인코포레이티드 |
핵산 분자 및 그 사용 방법
|
|
US20210290708A1
(en)
|
2018-09-21 |
2021-09-23 |
Nantcell, Inc. |
Methods and compositions for modulating myeloid-derived suppressor cells
|
|
GB202010095D0
(en)
*
|
2020-07-01 |
2020-08-12 |
Tcer Ab |
Immunotherapy
|